Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Research Output

2020

Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Brewer, M. R., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & 2 others, Hanker, A. B. & Arteaga, C. L., Feb 10 2020, In : Cancer Cell. 37, 2, p. 258-259 2 p.

Research output: Contribution to journalComment/debate

Open Access

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Red Brewer, M., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & 2 others, Hanker, A. B. & Arteaga, C. L., Feb 10 2020, In : Cancer Cell. 37, 2, p. 183-199.e5

Research output: Contribution to journalArticle

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study

Azad, N. S., Gray, R. J., Overman, M. J., Schoenfeld, J. D., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Streicher, H., Li, S., McShane, L. M., Rubinstein, L., Patton, D. R., Williams, P. M., Coffey, B., Hamilton, S. R., Bahary, N., Suga, J. M., Hatoum, H., Abrams, J. S., Conley, B. A. & 5 others, Arteaga, C. L., Harris, L., O'Dwyer, P. J., Chen, A. P. & Flaherty, K. T., Jan 20 2020, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38, 3, p. 214-222 9 p.

Research output: Contribution to journalArticle

Overcoming Endocrine Resistance in Breast Cancer

Hanker, A. B., Sudhan, D. R. & Arteaga, C. L., Apr 13 2020, In : Cancer Cell. 37, 4, p. 496-513 18 p.

Research output: Contribution to journalReview article

Trametinib activity in patients with solid tumors and lymphomas harboring braf non-V600 mutations or fusions: Results from NCI-MATCH (EAY131)

Johnson, D. B., Zhao, F., Noel, M., Riely, G. J., Mitchell, E. P., Wright, J. J., Chen, H. X., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O'Dwyer, P. J., Chen, A. P. & Flaherty, K. T., Apr 15 2020, In : Clinical Cancer Research. 26, 8, p. 1812-1819 8 p.

Research output: Contribution to journalArticle

Open Access

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer

Rugo, H. S., Bardia, A., Tolaney, S. M., Arteaga, C., Cortes, J., Sohn, J., Marmé, F., Hong, Q., Delaney, R. J., Hafeez, A., André, F. & Schmid, P., Apr 2020, In : Future Oncology. 16, 12, p. 705-712 8 p.

Research output: Contribution to journalArticle

Open Access
2019

Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors

Hanker, A. B., Kaklamani, V. & Arteaga, C. L., Apr 2019, In : Cancer discovery. 9, 4, p. 482-491 10 p.

Research output: Contribution to journalArticle

17 Scopus citations

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ERþ/HER2 mutant breast cancer

Croessmann, S., Formisano, L., Kinch, L. N., Gonzalez-Ericsson, P. I., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E. H., Cristofanilli, M., He, J., Cutler, R. E., Lalani, A. S., Miller, V. A., Lanman, R. B., Grishin, N. V. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 277-289 13 p.

Research output: Contribution to journalArticle

10 Scopus citations
Open Access
Open Access

Correction: 18 F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)

Wang, Y., Ayres, K. L., Goldman, D. A., Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E., Fredrickson, J., Arteaga, C. L., Baselga, J., Manning, H. C., Mahmood, U. & Ulaner, G. A., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and Notch-dependent cancer stem cell population (Cancer Research (2016) 76 (440–452) DOI: 10.1158/0008-5472.CAN-15-1640-T)

Bhola, N. E., Jansen, V. M., Koch, J. P., Li, H., Formisano, L., Williams, J. A., Grandis, J. R. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J. J., Perez-Fidalgo, A., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V. & 2 others, Ruiz-Simon, A. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: Pik3ca c2 domain deletions hyperactivate phosphoinositide 3-kinase (pi3k), generate oncogene dependence, and are exquisitely sensitive to pi3ka inhibitors(Clin Cancer Res (2018) 24 (1426–35)DOI: 10.1158/1078-0432.CCR-17-2141)

Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., Sanchez, V., Sanders, M. E., Cook, R. S., Pilkinton, M. A., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., Doimi, F. D. & 5 others, Gomez, H., Ryzhov, S. V., Darcy, P. K., Arteaga, C. L. & Balko, J. M., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
3 Scopus citations

Correction: Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer (Cancer Research (2015) 75 (405–414) DOI: 10.1158/0008-5472.CAN-14-2475)

Bhola, N. E., Jansen, V. M., Bafna, S., Giltnane, J. M., Balko, J. M., Estrada, M. V., Meszoely, I., Mayer, I., Abramson, V., Ye, F., Sanders, M., Dugger, T. C., Allen, E. V. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2(Clin Cancer Res. (2017) 23:15 (4323-4334) DOI: 10.1158/1078-0432.CCR-16-2287)

Hanker, A. B., Garrett, J. T., Valeria Estrada, M., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S. & 6 others, Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer (Cancer Research (2017) 77 (3280–3292) DOI: 10.1158/0008-5472.CAN-16-2808)

Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sánchez, V., Rexer, B. N., Sanders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Feb 15 2019, In : Cancer research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction: Association of FGFR1 with ERA maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER þ breast cancer (Clinical Cancer Research (2019)23 (6138–6150) Doi:10.1158/1078-0432.CCR-17-1232)

Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Angel, L. G. Z., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., Lu, Y., Balko, J. M., Deas, O., Cairo, S., Judde, J. G., Mayer, I. A., Sanders, M., Dugger, T. C., Bianco, R., Stricker, T. & 1 others, Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C. L. & Neven, P., Jan 1 2019, (Accepted/In press) In : Clinical Drug Investigation.

Research output: Contribution to journalArticle

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J. L., Arnold, A. L., Fogarty, S. A., Perry, E., Ramsey, H. E., Cook, R. S., Hollingshead, M., Davis Millin, M., Lee, K. M., Koss, B., Budhraja, A. & 7 others, Opferman, J. T., Kim, K., Arteaga, C. L., Moore, W. J., Olejniczak, E. T., Savona, M. R. & Fesik, S. W., Apr 25 2019, In : Journal of Medicinal Chemistry. 62, 8, p. 3971-3988 18 p.

Research output: Contribution to journalArticle

10 Scopus citations

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Patel, H. K., Tao, N., Lee, K. M., Huerta, M., Arlt, H., Mullarkey, T., Troy, S., Arteaga, C. L. & Bihani, T., Dec 18 2019, In : Breast Cancer Research. 21, 1, 146.

Research output: Contribution to journalArticle

Open Access

Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of oncology : official journal of the European Society for Medical Oncology (2018) 29 7 (1541-1547) PII: S0923-7534(20)32578-3)

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C. & 1 others, O'Shaughnessy, J., Nov 1 2019, In : Annals of oncology : official journal of the European Society for Medical Oncology. 30, 11, 1 p.

Research output: Contribution to journalComment/debate

Open Access

Erratum: Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer (eLife (2016) 5 PII: e44851)

Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K. & 26 others, Moon, M., Prudente, R., Bischoff, E., Lee, K. J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C. & Hager, J. H., Jan 7 2019, In : eLife. 8

Research output: Contribution to journalComment/debate

Erratum: Triple-negative breast cancers with amplication of JAK2 at the 9p24 locus demonstrate JAK2-specic dependence (Science Translational Medicine (2019) 11, 476, (eaaw6162), 10.1126/scitranslmed.aaw6162)

Balko, J. M., Schwarz, L. J., Luo, N., Estrada, M. V., Giltnane, J. M., Dávila-González, D., Wang, K., Sánchez, V., Dean, P. T., Combs, S. E., Hicks, D., Pinto, J. A., Landis, M. D., Doimi, F. D., Yelensky, R., Miller, V. A., Stephens, P. J., Rimm, D. L., Gómez, H., Chang, J. C. & 3 others, Sanders, M. E., Cook, R. S. & Arteaga, C. L., Jan 23 2019, In : Science Translational Medicine. 11, 476, eaaw6162.

Research output: Contribution to journalReview article

Erratum for the research article: Genomic proling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (Science Translational Medicine DOI: 10.1126/scitranslmed.aai7993)

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V., Ericsson, P. G., Kuba, M. G., Sanders, M. E., Mu, X. J., Van Allen, E. M., Wagle, N., Mayer, I. A., Abramson, V., Gόmez, H., Rizzo, M., Toy, W. & 15 others, Chandarlapaty, S., Mayer, E. L., Christiansen, J., Murphy, D., Fitzgerald, K., Wang, K., Ross, J. S., Miller, V. A., Stephens, P. J., Yelensky, R., Garraway, L., Shyr, Y., Meszoely, I., Balko, J. M. & Arteaga, C. L., Feb 13 2019, In : Science Translational Medicine. 11, 479, eaaw7620.

Research output: Contribution to journalComment/debate

Erratum for The research article: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation (Science Translational Medicine DOI: 10.1126/scitranslmed.aal4682)

Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M., Goel, S., Qi, X., Shankaraiah, R., Cao, Z. A., Ramjiawan, R. R., Bezwada, D., Patel, B., Song, Y., Costa, C., Naxerova, K., Wong, C. S. F., Kloepper, J., Das, R., Tam, A., Tanboon, J. & 13 others, Duda, D. G., Miller, C. R., Siegel, M. B., Anders, C. K., Sanders, M., Estrada, M. V., Schlegel, R., Arteaga, C. L., Brachtel, E., Huang, A., Fukumura, D., Engelman, J. A. & Jain, R. K., Jan 30 2019, In : Science Translational Medicine. 11, 477, aaw6935.

Research output: Contribution to journalComment/debate

Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

Viswanadhapalli, S., Ma, S., Sareddy, G. R., Lee, T. K., Li, M., Gilbreath, C., Liu, X., Luo, Y., Pratap, U. P., Zhou, M., Blatt, E. B., Kassees, K., Arteaga, C., Alluri, P., Rao, M., Weintraub, S. T., Tekmal, R. R., Ahn, J. M., Raj, G. V. & Vadlamudi, R. K., Dec 26 2019, In : Breast Cancer Research. 21, 1, 150.

Research output: Contribution to journalArticle

Open Access
3 Scopus citations

Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ERþ/HER2þ breast cancers: Implications to the EXTENET trial

Sudhan, D. R., Schwarz, L. J., Guerrero-Zotano, A., Formisano, L., Nixon, M. J., Croessmann, S., Gonzalez Ericsson, P. I., Sanders, M., Balko, J. M., Avogadri-Connors, F., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & Arteaga, C. L., Jan 15 2019, In : Clinical Cancer Research. 25, 2, p. 771-783 13 p.

Research output: Contribution to journalArticle

4 Scopus citations

FGFR1 amplification mediates endocrine resistance but retains torc sensitivity in metastatic hormone receptor-positive (HR+) breast cancer

Drago, J. Z., Formisano, L., Juric, D., Niemierko, A., Servetto, A., Wander, S. A., Spring, L. M., Vidula, N., Younger, J., Peppercorn, J., Yuen, M., Malvarosa, G., Sgroi, D., Isakoff, S. J., Moy, B., Ellisen, L. W., Iafrate, A. J., Arteaga, C. L. & Bardia, A., Nov 1 2019, In : Clinical Cancer Research. 25, 21, p. 6443-6451 9 p.

Research output: Contribution to journalArticle

2 Scopus citations

Financial incentives to promote colorectal cancer screening: A longitudinal randomized control trial

Lieberman, A., Gneezy, A., Berry, E., Miller, S., Koch, M., Ahn, C., Balasubramanian, B. A., Argenbright, K. E. & Gupta, S., Jan 1 2019, In : Cancer Epidemiology Biomarkers and Prevention. 28, 11, p. 1902-1908 7 p.

Research output: Contribution to journalArticle

Open Access

Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

Unni, N. & Arteaga, C. L., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journalComment/debate

1 Scopus citations

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

Nixon, M. J., Formisano, L., Mayer, I. A., Estrada, M. V., González-Ericsson, P. I., Isakoff, S. J., Forero-Torres, A., Won, H., Sanders, M. E., Solit, D. B., Berger, M. F., Cantley, L. C., Winer, E. P., Arteaga, C. L. & Balko, J. M., Dec 1 2019, In : npj Breast Cancer. 5, 1, 31.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells

Chakrabarty, A., Surendran, S., Bhola, N. E., Mishra, V. S., Wani, T. H., Baghel, K. S., Arteaga, C. L., Garg, R. & Chowdhury, G., Oct 16 2019, In : Carcinogenesis. 40, 10, p. 1179-1190 12 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations
2018

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

Campone, M., Im, S. A., Iwata, H., Clemons, M., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Cortés, J., De Laurentiis, M., Arteaga, C. L., Jiang, Z., Jonat, W., Le Mouhaër, S., Sankaran, B., Bourdeau, L. & 3 others, El-Hashimy, M., Sellami, D. & Baselga, J., Nov 1 2018, In : European Journal of Cancer. 103, p. 147-154 8 p.

Research output: Contribution to journalArticle

14 Scopus citations

Correction: Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer (Cancer Research (2017) 77 (2488-2499) DOI: 10.1158/0008-5472)

Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K. M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., Ericsson, P. G., Sanders, M. E., Pohlmann, P. R., Pishvaian, M. J., Riddle, D. A., Dugger, T. C., Wei, W., Knudsen, E. S. & Arteaga, C. L., Feb 15 2018, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Garrett, J. T., Chakrabarty, A. & Arteaga, C. L., Aug 17 2018, In : Oncotarget. 9, 64, p. 32400 1 p.

Research output: Contribution to journalComment/debate

Effects of program scale-up on time to resolution for patients with abnormal screening mammography results

Lee, S. C., Higashi, R. T., Sanders, J. M., Zhu, H., Inrig, S. J., Mejias, C., Argenbright, K. E. & Tiro, J. A., Oct 1 2018, In : Cancer Causes and Control. 29, 10, p. 995-1005 11 p.

Research output: Contribution to journalArticle

1 Scopus citations

ERþ Breast cancers resistant to prolonged neoadjuvant letrozole exhibit an e2f4 transcriptional program sensitive to cdk4/6 inhibitors

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J., Alejandro, J. P. F., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V. & 2 others, Ruiz-Simon, A. & Arteaga, C. L., Jun 1 2018, In : Clinical Cancer Research. 24, 11, p. 2517-2529 13 p.

Research output: Contribution to journalArticle

11 Scopus citations

HER kinase inhibition in patients with HER2-and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 others, Beer, H., Duygu Selcuklu, S., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 8 2018, In : Nature. 554, 7691, p. 189-194 6 p.

Research output: Contribution to journalArticle

162 Scopus citations

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

Luo, N., Formisano, L., Gonzalez-Ericsson, P. I., Sanchez, V., Dean, P. T., Opalenik, S. R., Sanders, M. E., Cook, R. S., Arteaga, C. L., Johnson, D. B. & Balko, J. M., Jun 3 2018, In : OncoImmunology. 7, 6, e1438106.

Research output: Contribution to journalArticle

10 Scopus citations

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program

Pulley, J. M., Jerome, R. N., Ogletree, M. L., Bernard, G. R., Lavieri, R. R., Zaleski, N. M., Hong, C. C., Shirey-Rice, J. K., Arteaga, C. L., Mayer, I. A., Holroyd, K. J. & Cook, R. S., Feb 1 2018, In : Targeted Oncology. 13, 1, p. 61-68 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

Neratinib: Inching up on the cure rate of HER2+ breast cancer?

Unni, N., Sudhan, D. R. & Arteaga, C. L., Aug 1 2018, In : Clinical Cancer Research. 24, 15, p. 3483-3485 3 p.

Research output: Contribution to journalArticle

2 Scopus citations

PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors

Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J. & Arteaga, C. L., Mar 15 2018, In : Clinical Cancer Research. 24, 6, p. 1426-1435 10 p.

Research output: Contribution to journalArticle

7 Scopus citations

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

O’Shaughnessy, J., Petrakova, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D. A., Hart, L. L., Villanueva, C., Jakobsen, E., Beck, J. T., Lindquist, D., Souami, F., Mondal, S., Germa, C. & Hortobagyi, G. N., Feb 1 2018, In : Breast Cancer Research and Treatment. 168, 1, p. 127-134 8 p.

Research output: Contribution to journalArticle

30 Scopus citations

TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association

Zonneville, J., Safina, A., Truskinovsky, A. M., Arteaga, C. L. & Bakin, A. V., Jun 19 2018, In : BMC Cancer. 18, 1, 670.

Research output: Contribution to journalArticle

10 Scopus citations

The attenuation distribution across the long axis of breast cancer liver metastases at CT: A quantitative biomarker for predicting overall survival

Abramson, R. G., Lakomkin, N., Hainline, A., Kang, H., Hutson, M. S. & Arteaga, C. L., Jan 1 2018, In : American Journal of Roentgenology. 210, 1, p. W1-W7

Research output: Contribution to journalArticle

2 Scopus citations

Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C. & Neven, P., Nov 1 2018, In : Clinical Drug Investigation. 38, 11, p. 1071-1075 5 p.

Research output: Contribution to journalArticle

2 Scopus citations